Clinical efficacy of stellate ganglion block combined with betahistine hydrochloride in the treatment of vestibular migraine

In this study, 100 patients with vestibular migraine treated in our hospital from January 2022 to January 2024 were selected and divided into experimental group and control group according to their willingness to treat, with 50 patients in each group. The control group was treated with betahistine hydrochloride, and the experimental group was treated with stellate ganglion block combined with betahistine hydrochloride under ultrasound guidance. The level of headache, vertigo symptoms, sleep quality, continuous time of migraine and treatment efficiency were compared between the two groups before and after treatment. The scores of NRS, DHI and PSQI were similar in the two groups before treatment (P > 0.05), and the scores of these indexes in the experimental group were lower than those in the control group after treatment (P < 0.05). The time of continuous migraine in the experimental group was shorter than that in the control group, and the effective rate of the experimental group was 92.00%, which was significantly higher than that of the control group (80%). Ultrasound-guided stellate ganglion block combined with betahistine hydrochloride is very effective in the treatment of adult vestibular migraine, which can significantly improve clinical signs symptoms such as headache, dizziness, sleep and so on, and has a good promotion value in clinical medicine.